» Articles » PMID: 37578489

Cognitive Impairment and Dementia in Young Onset Parkinson's Disease

Abstract

Background And Objective: Patients with young-onset Parkinson's disease (YOPD) have a slower progression. Our aim was to analyze the change in cognitive function in YOPD compared to patients with a later onset and controls.

Patients And Methods: Patients with Parkinson's disease (PD) and controls from the COPPADIS cohort were included. Cognitive function was assessed with the Parkinson's Disease Cognitive Rating Scale (PD-CRS) at baseline (V0), 2-year ± 1 month (V2y), and 4-year ± 3 months follow-up (V4y). Regarding age from symptoms onset, patients were classified as YOPD (< 50 years) or non-YOPD (≥ 50). A score in the PD-CRS < 81 was defined as cognitive impairment (CI): ≤ 64 dementia; 65-80 mild cognitive impairment (MCI).

Results: One-hundred and twenty-four YOPD (50.7 ± 7.9 years; 66.1% males), 234 non-YOPD (67.8 ± 7.8 years; 59.3% males) patients, and 205 controls (61 ± 8.3 years; 49.5% males) were included. The score on the PD-CRS and its subscore domains was higher at all visits in YOPD compared to non-YOPD patients and to controls (p < 0.0001 in all analysis), but no differences were detected between YOPD patients and controls. Only non-YOPD patients had significant impairment in their cognitive function from V0 to V4y (p < 0.0001). At V4y, the frequency of dementia and MCI was 5% and 10% in YOPD compared to 25.2% and 22.3% in non-YOPD patients (p < 0.0001). A lower score on the Parkinson's Disease Sleep Scale at baseline was a predictor of CI at V4y in YOPD patients (Adjusted R = 0.61; OR = 0.965; p = 0.029).

Conclusion: Cognitive dysfunction progressed more slowly in YOPD than in non-YOPD patients.

Citing Articles

Levodopa-Induced Dyskinesias are Frequent and Impact Quality of Life in Parkinson's Disease: A 5-Year Follow-Up Study.

Santos-Garcia D, de Deus T, Cores C, Feal Painceiras M, Iniguez Alvarado M, Samaniego L Mov Disord Clin Pract. 2024; 11(7):830-849.

PMID: 38747234 PMC: 11233927. DOI: 10.1002/mdc3.14056.


Reduced Prevalence of Parkinson's Disease in Patients Prescribed Calcineurin Inhibitors.

Silva J, Jupiter D, Taglialatela G J Parkinsons Dis. 2024; 14(3):533-543.

PMID: 38427501 PMC: 11091574. DOI: 10.3233/JPD-230313.


Pathobiology of Cognitive Impairment in Parkinson Disease: Challenges and Outlooks.

Jellinger K Int J Mol Sci. 2024; 25(1).

PMID: 38203667 PMC: 10778722. DOI: 10.3390/ijms25010498.

References
1.
Greenland J, Williams-Gray C, Barker R . The clinical heterogeneity of Parkinson's disease and its therapeutic implications. Eur J Neurosci. 2018; 49(3):328-338. DOI: 10.1111/ejn.14094. View

2.
Titova N, Padmakumar C, Lewis S, Chaudhuri K . Parkinson's: a syndrome rather than a disease?. J Neural Transm (Vienna). 2016; 124(8):907-914. PMC: 5514217. DOI: 10.1007/s00702-016-1667-6. View

3.
Hughes A, Daniel S, Kilford L, Lees A . Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992; 55(3):181-4. PMC: 1014720. DOI: 10.1136/jnnp.55.3.181. View

4.
Postuma R, Berg D, Stern M, Poewe W, Olanow C, Oertel W . MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015; 30(12):1591-601. DOI: 10.1002/mds.26424. View

5.
Post B, van den Heuvel L, van Prooije T, van Ruissen X, van de Warrenburg B, Nonnekes J . Young Onset Parkinson's Disease: A Modern and Tailored Approach. J Parkinsons Dis. 2020; 10(s1):S29-S36. PMC: 7592661. DOI: 10.3233/JPD-202135. View